Clinical UM Guideline |
Subject: Fundus Photography | |
Guideline #: CG-MED-47 | Publish Date: 04/10/2024 |
Status: Reviewed | Last Review Date: 02/15/2024 |
Description |
This document addresses the uses of fundus photography. Fundus photography uses a retinal camera to photograph regions of the vitreous, retina, choroid, and optic nerve to document abnormalities related to disease processes affecting the eye or to follow the progress of the disease in response to therapy. The photographs can be taken with analog or digital photography.
Note: Please see the following related document for additional information:
Clinical Indications |
Medically Necessary:
Not Medically Necessary:
Coding |
The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
When services may be Medically Necessary when criteria are met:
CPT |
|
92250 | Fundus photography with interpretation and report |
|
|
ICD-10 Diagnosis |
|
| All diagnoses except those listed as ‘not medically necessary’, including, but not limited to: |
A18.50-A18.59 | Tuberculosis of eye |
A50.01 | Early congenital syphilitic oculopathy |
A50.30 | Late congenital syphilitic oculopathy, unspecified |
A50.44 | Late congenital syphilitic optic nerve atrophy |
A51.43 | Secondary syphilitic oculopathy |
A52.15 | Late syphilitic neuropathy |
A52.71 | Late syphilitic oculopathy |
B20 | Human immunodeficiency virus [HIV] disease |
B25.0-B25.9 | Cytomegalovirus disease |
B39.4-B39.9 | Histoplasmosis |
B50.0-B52.9 | Malaria |
B58.00-B58.09 | Toxoplasma oculopathy |
C69.00-C69.92 | Malignant neoplasm of eye and adnexa |
C79.49 | Secondary malignant neoplasm of other parts of nervous system |
D09.20-D09.22 | Carcinoma in situ of eye |
D31.00-D31.92 | Benign neoplasm of eye and adnexa |
D33.3 | Benign neoplasm of cranial nerves |
D49.81 | Neoplasm of unspecified behavior of retina and choroid |
D57.00-D57.819 | Sickle-cell disorders |
E08.00-E13.9 | Diabetes mellitus |
E50.7 | Other ocular manifestations of vitamin A deficiency |
E70.310-E70.329 | Ocular/oculocutaneous albinism |
G35 | Multiple sclerosis |
G45.3 | Amaurosis fugax |
G93.2 | Benign intracranial hypertension [pseudotumor cerebri] |
H15.031-H15.039 | Posterior scleritis |
H16.241-H16.249 | Ophthalmia nodosa |
H20.821-H20.829 | Vogt-Koyanagi syndrome |
H21.331-H21.339 | Parasitic cyst of iris, ciliary body or anterior chamber |
H27.111-H27.139 | Subluxation/dislocation of lens |
H30.001-H30.93 | Chorioretinal inflammation |
H31.001-H31.9 | Other disorders of choroid |
H32 | Chorioretinal disorders in diseases classified elsewhere |
H33.001-H33.8 | Retinal detachments and breaks |
H34.00-H34.9 | Retinal vascular occlusions |
H35.00-H35.9 | Retinopathy of prematurity |
H36.811-H36.89 | Retinal disorders in diseases classified elsewhere |
H40.001-H40.9 | Glaucoma |
H42 | Glaucoma in diseases classified elsewhere |
H43.00-H43.9 | Disorders of vitreous body |
H44.001-H44.9 | Disorders of globe |
H46.00-H46.9 | Optic neuritis |
H47.011-H47.9 | Other disorders of optic (2nd) nerve and visual pathways |
H53.121-H53.15 | Visual loss/visual disturbances |
H53.40-H53.489 | Visual field defects |
H53.50-H53.59 | Color vision deficiencies |
H53.63 | Congenital night blindness |
H53.71-H53.9 | Vision sensitivity deficiencies, other/unspecified visual disturbances |
L93.0-L93.2 | Lupus erythematosus |
M05.00-M05.9 | Rheumatoid arthritis |
M06.00-M06.9 | Other rheumatoid arthritis |
M08.00-M08.9A | Juvenile rheumatoid arthritis, other/unspecified juvenile arthritis |
M32.19 | Other organ or system involvement in systemic lupus erythematosus |
M32.8-M32.9 | Systemic lupus erythematosus, unspecified |
P35.0-P35.9 | Congenital viral diseases |
P37.0-P37.9 | Other congenital infectious and parasitic diseases |
Q14.0-Q14.9 | Congenital malformation of posterior segment of eye |
Q15.0 | Congenital glaucoma |
Q85.1-Q85.9 | Tuberous sclerosis, other/unspecified phakomatoses |
Q87.0-Q87.89 | Other specified congenital malformation syndromes affecting multiple systems |
R44.1 | Visual hallucinations |
R48.3 | Visual agnosia |
R94.110-R94.118 | Abnormal results of function studies of eye |
S05.00XA-S05.92XS | Injury of eye and orbit |
T37.2X1A-T37.2X5S | Poisoning by, adverse effect of antimalarials and drugs acting on other blood protozoa |
T74.12XA-T74.12XS | Child physical abuse, confirmed |
T74.4XXA-T74.4XXS | Shaken infant syndrome |
T76.12XA-T76.12XS | Child physical abuse, suspected |
Z08-Z09 | Encounter for follow-up examination after completed treatment for malignant neoplasm, other than malignant neoplasm |
Z79.899 | Other long term (current) drug therapy |
Z85.840 | Personal history of malignant neoplasm of eye |
When services are Not Medically Necessary:
For the procedure code listed above when criteria are not met, for the following diagnosis codes, or for situations designated in the Clinical Indications section as not medically necessary.
ICD-10 Diagnosis |
|
Z01.00 | Encounter for examination of eyes and vision without abnormal findings |
Z13.5 | Encounter for screening for eye and ear disorders |
When services are also Not Medically Necessary:
For the following procedure code, or when the code describes a procedure designated in the Clinical Indications section as not medically necessary.
CPT |
|
92499 | Unlisted ophthalmological service or procedure [when specified as computer-aided animation and analysis of time series retinal images for the monitoring of disease progression, unilateral or bilateral, with interpretation and report] |
|
|
ICD-10 Diagnosis |
|
| All diagnoses |
Discussion/General Information |
Imaging of the fundus is useful to check its status and assess for any changes from a healthy condition of the eye. Fundus imaging can focus on the structure or function of the retina or diagnose ocular diseases. Retinoscopy allows direct visualization of small vessels and nerves and can be used to detect early signs of diseases that affect the eyes, circulation, or the brain. Conditions detectable by retinoscopy include glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and systemic diseases such as multiple sclerosis.
Diabetic retinopathy causes damage to the blood vessels in the retina. It is the most common diabetic eye disease and is a leading cause of blindness in American adults. It is caused by changes in the blood vessels of the retina. A 2013 study by Ku and colleagues reported on 360 individuals (706 eyes) who had fundus photographs and self-reported diabetes. Upon clinical grading of the photographs, 163 eyes had diabetic retinopathy and 51 eyes had vision-threatening diabetic retinopathy. The sensitivity for detecting diabetic retinopathy was 74% with a specificity of 92%; for vision-threatening diabetic retinopathy, sensitivity was 86% and specificity was 95%. The authors concluded that fundus photography was a valid screening tool for diabetic retinopathy.
The American Academy of Ophthalmology (AAO) 2019 Preferred Practice Pattern® (PPP) for diabetic retinopathy reports that the use of fundus photography has little value in cases with minimal diabetic retinopathy or when the diabetic retinopathy is unchanged from prior photographs, but fundus photography may be useful for documenting disease progression and treatment response. This PPP also encourages annual dilated eye screening exams for those with Type 2 diabetes mellitus who have not developed retinopathy or fundus photography screening stating:
Given the known gap in accessibility of direct ophthalmologic screening, fundus photographic screening programs may help increase the chances that at-risk individuals will be promptly referred for more detailed evaluation and management.
In summary, the AAO’s support of fundus photography in screening for diabetic retinopathy is only in light of potential inaccessibility to ophthalmic exams. Evidence comparing the use of fundus photography to standard screening by direct visualization is lacking.
Glaucoma is a group of diseases that damage the optic nerve of the eye and can lead to vision loss and blindness. The AAO has published a PPP Summary Benchmark for primary open-angle glaucoma (2020) and suspected primary open-angle glaucoma (2020) and recommended examination of the retinal nerve fiber layer of the fundus to include photography for both conditions. While the most desirable techniques for evaluating the optic nerve head and retinal nerve fiber layer are stereophotography or computer-based imaging, a nonstereoscopic photograph is an alternative.
AMD is a disorder of the macula which generally affects older adults and is characterized by loss of vision in the macula (center of the field of vision) caused by damage to the retina. Both ‘dry’ and ‘wet’ forms of AMD are major causes of blindness and visual deficits in developed countries. It was estimated that approximately 1.75 million people over the age of 40 in the United States (U.S.) were affected in at least one eye in 2004, with estimates of nearly 3 million to be affected by 2020 and an anticipated increase to 22 million by the year 2050 (AAO, 2020). The AAO PPP for AMD (2019) recommends, “Color fundus photographs may be obtained when angiography is performed, because they are useful in finding landmarks, evaluating serous detachments of the neurosensory retina and RPE [retinal pigment epithelium], and determining the etiology of blocked fluorescence.” There is no recommendation by the AAO for fundus photography use as a screening tool in AMD.
Recommendations by the AAO (Marmor, 2011) do not advise the use of fundus photography for screening for chloroquine and hydroxychloroquine retinopathy from anti-malarial medication. They state that fundus photography should be used for documentation and monitoring purposes, but if bull’s eye maculopathy is visible, this is considered to be a late change and the goal of screening is to find toxicity at an earlier stage.
MatchedFlicker® (EyeIC, Wayne, PA) received U.S. Food and Drug Administration (FDA) 501(k) premarket approval (PMA) in 2009 and is described as “a software program that is intended for use by health care professionals to collect, store, and spatially calibrate (i.e. register and align) images of the posterior segment of the human eye” (FDA, 2009). The majority of the literature on MatchedFlicker consists of small case studies or are non-comparative in nature. While some large-scale studies suggest that MatchedFlicker may be as effective or even more reliable than standard medical practices, its role in improving clinical results is not yet clear. (Cymbor, 2009; Syed 2012; VanderBeek, 2010). Additionally, no specialty guidelines recommend the use of MatchedFlicker technology in fundus photography analysis.
Definitions |
Choroid: The vascular layer of the eye that lies between the retina and the sclera. It provides nourishment to outer layers of the retina.
Fundus: The interior surface of the eye, opposite the lens. The fundus includes the retina, optic disc, macula, fovea, and posterior pole.
Glaucoma: A disease characterized by destruction of the nerve fiber layer of the optic disc.
Optic nerve: The nerve that carries images of what is seen from the eye to the brain.
Retina: The light-sensitive layer of tissue that lines the inside of the eye and sends visual messages through the optic nerve to the brain.
Vitreous body: A transparent jellylike substance that fills the posterior segment of the eye, delimited by the hyaloid membrane.
References |
Peer Reviewed Publications:
Government Agency, Medical Society, and Other Authoritative Publications:
Websites for Additional Information |
Index |
Fundus photography
History |
Status | Date | Action |
Reviewed | 02/15/2024 | Medical Policy & Technology Assessment Committee (MPTAC) review. Updated Description, Discussion/General Information and References section. |
| 09/27/2023 | Updated Coding section with 10/01/2023 ICD-10-CM changes; added H36.811-H36.89 replacing H36. |
Reviewed | 02/16/2023 | MPTAC review. Updated Discussion/General Information and References section. Updated Coding section with additional diagnosis code examples. |
Reviewed | 02/17/2022 | MPTAC review. Updated Discussion/General Information and References section. Updated Coding section with corrected diagnosis ranges (H30.001 and H30.811). |
Reviewed | 02/11/2021 | MPTAC review. Updated Discussion/General Information and References section. Reformatted Coding section. |
| 10/01/2020 | Updated Coding section with 10/01/2020 ICD-10-CM changes; added M06.0A. |
Reviewed | 02/20/2020 | MPTAC review. Updated Discussion/General Information and References section. |
| 12/31/2019 | Updated Coding section with 01/01/2020 CPT changes; added 92499 replacing 0380T deleted 12/31/2019. |
Reviewed | 03/21/2019 | MPTAC review. Updated References section. |
Reviewed | 03/22/2018 | MPTAC review. Updated header language from “Current Effective Date” to “Publish Date.” Updated Coding and References section. |
Reviewed | 05/04/2017 | MPTAC review. Updated Discussion/General Information, Coding and References sections. |
| 10/01/2016 | Updated Coding section to include 10/01/2016 ICD-10-CM diagnosis code changes. |
Reviewed | 05/05/2016 | MPTAC review. Updated Discussion/General Information and References sections. Removed ICD-9 codes from Coding section. |
Revised | 05/07/2015 | MPTAC review. Added MatchedFlicker to NMN Criteria. Updated Description, Coding, Discussion/General Information and References sections. |
Reviewed | 05/15/2014 | MPTAC review. Updated General Information/Background, References and History sections. |
New | 05/09/2013 | MPTAC review. Initial document development. |
Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.
Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.
No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.
© CPT Only - American Medical Association